Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.52 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21875106 | 0.87 | KLKB1 (0.49) | GRM4KLKB1NAMPTPKMCA1 | |
| SCHEMBL21875096 | 0.85 | KLKB1 (0.50) | GRM4KLKB1NAMPT | |
| SCHEMBL21875147 | 0.82 | KLKB1 (0.62) | KLKB1PKMMAPT | |
| SCHEMBL21875103 | 0.81 | KLKB1 (0.49) | GRM4KLKB1NAMPTPKMCA1 | |
| SCHEMBL21875123 | 0.80 | KCNJ1 (0.58) | GRM4KLKB1MAPT | |
| SCHEMBL16639000 | 0.78 | KLKB1 (0.80) | KLKB1 | |
| SCHEMBL21875145 | 0.77 | PKM (0.52) | GRM4KLKB1NAMPTPKM | |
| SCHEMBL21875086 | 0.75 | KLKB1 (0.49) | KLKB1NAMPT | |
| SCHEMBL21875153 | 0.75 | GRM4 (0.50) | GRM4KLKB1NAMPT | |
| SCHEMBL21875171 | 0.73 | KLKB1 (0.49) | GRM4KLKB1NAMPTPKMCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113056461-A | Arylsulfonyl pyrrole carboxamide derivatives as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | claimed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | claimed |
| CN-113056461-A | Arylsulfonyl pyrrole carboxamide derivatives as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | disclosed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | KCNA3, KCNN3, KCNK3 | GRM4 1103/4885KLKB1 784/4885NAMPT 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.